abacavir, lamivudine, and zidovudine drug combination

a combination of abacavir / lamivudine / zidovudine

Also Known As:

Trizivir; abacavir - lamivudine - zidovudine drug combination; abacavir, lamivudine, zidovudine drug combination; abacavir-lamivudine-zidovudin

Networked: 11 relevant articles (0 outcomes, 3 trials/studies)

Drug Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclopropanes: 9
        abacavir, lamivudine, and zidovudine drug combination: 11
Pharmaceutical Preparations
- Drug Combinations: 5337
  - abacavir, lamivudine, and zidovudine drug combination: 11
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - Pyrimidine Nucleosides: 50
      - Thymidine: 4460
        Zidovudine: 3074
        abacavir, lamivudine, and zidovudine drug combination: 11
      - Cytidine: 535
        Deoxycytidine: 307
        Zalcitabine: 278
        Lamivudine: 3620
        abacavir, lamivudine, and zidovudine drug combination: 11
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Purine Nucleosides: 360
        Adenosine: 12431
        Deoxyadenosines: 1
        Dideoxyadenosine: 14
        abacavir, lamivudine, and zidovudine drug combination: 11
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847

Experts

1.	Moreno, V: 1 article (01/2012)
2.	Valencia, M E: 1 article (01/2012)
3.	Kongnyuy, Eugene J: 1 article (07/2009)
4.	Shang, Judith: 1 article (07/2009)
5.	Shey, Muki: 1 article (07/2009)
6.	Wiysonge, Charles Shey: 1 article (07/2009)
7.	Mastroianni, Claudio M: 1 article (11/2006)
8.	Vullo, Vincenzo: 1 article (11/2006)
9.	d'Ettorre, Gabriella: 1 article (11/2006)
10.	Handforth, Jennifer: 1 article (01/2004)

Related Diseases

1.	Infections 11/01/2003 - "Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial." 02/14/2003 - "Effect of co-formulated zidovudine, lamivudine and abacavir (Trizivir) on antiretroviral-naive patients presenting with advanced HIV-1 infection." 01/01/2012 - "The patient was under clinically and virologically effective treatment with Trizivir (zidovudine, lamivudine and abacavir) when it was decided to initiate treatment for the chronic HCV infection with peginterferon and ribavirin. "
2.	Acquired Immunodeficiency Syndrome (AIDS) 01/01/2004 - "A major concern is the apparently inferior virologic control of triple NRTI therapy as demonstrated in the AIDS Clinical Trials Group A5095 study with zidovudine/lamivudine/abacavir (Trizivir) combination in adults. " 07/08/2009 - "A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS."
3.	Lipodystrophy 01/01/2003 - "Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study." 01/01/2003 - "To analyze the evolution of clinical lipodystrophy (LD) and metabolic abnormalities in patients continuing to receive HAART versus patients switched to Trizivir (zidovudine, lamivudine, abacavir) after 48 weeks. "
4.	HIV Infections (HIV Infection) 12/01/2000 - "FDA approves Trizivir for HIV infection." 07/08/2009 - "The aim of this review was to evaluate the effects of Trizivir, a fixed-dose combination of three NRTIs (abacavir-lamivudine-zidovudine) for initial treatment of HIV infection. " 11/01/2006 - "Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir." 07/08/2009 - "A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS."
5.	Hypersensitivity (Allergy) 07/08/2009 - "We found no significant differences between Trizivir and either the PI or NNRTI on CD4+ cell counts (standardized mean difference -0.01, 95% CI -0.11 to 0.09, heterogeneity P=0.59, I(2)=0%), severe adverse events (RR 1.41, 95% CI 0.61 to 3.25, heterogeneity P=0.03, I(2)=73%) and hypersensitivity reactions (RR 4.04, 95% CI 0.41 to 40.02, heterogeneity P=0.03, I(2)=72%). " 04/01/2003 - "The incidence of possible hypersensitivity reaction in the Trizivir trade mark arm was 10%. " 05/01/2002 - "Trizivir also avoids side effects of antiretroviral therapy, such as hyperlipidaemia, but its use is associated with a hypersensitivity reaction in a small number of patients. "

Related Drugs and Biologics

1.	abacavir (Ziagen)
2.	Zidovudine (Retrovir)
3.	Lamivudine (Epivir)
4.	zidovudine drug combination lamivudine
5.	Ribavirin (Virazole)
6.	Penicillin G Benzathine (Benzathine Benzylpenicillin)
7.	Nucleotides
8.	Nucleosides
9.	Drug Combinations
10.	Tenofovir (Viread)

Related Therapies and Procedures

1.	Therapeutics
2.	Highly Active Antiretroviral Therapy (HAART)